Quantcast

Latest G protein-coupled receptor Stories

2014-06-30 04:21:39

LONDON and BOSTON, June 30, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, is delighted to announce that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, has been invited to present at the Royal Society of Medicine Medical Innovations Summit. The event, which takes place on Saturday 5 July 2014 at The Royal Society of Medicine in London, UK, will feature presentations on pioneering...

2014-06-24 12:28:56

LONDON and BOSTON, June 24, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, announces that its President, Dan Grau, will present a company overview at the JMP Securities Healthcare Conference (24-25 June 2014, New York, NY, USA). His presentation will take place on 25 June at 9.30 am EDT. For a full list of events at which Heptares will be present, please visit http://www.heptares.com About...

2014-06-23 13:34:53

Duke University Medical Center A team of scientists from Duke Medicine, the University of Michigan and Stanford University has determined the underlying architecture of a cellular signaling complex involved in the body's response to stimuli such as light and pain. This complex, consisting of a human cell surface receptor and its regulatory protein, reveals a two-step mechanism that has been hypothesized previously but not directly documented. The findings, reported on June 22, 2014,...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....

2014-06-11 08:29:17

New antibodies generated with RuiYi's iCAPS technology to explore GPCR structure and function LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, a global therapeutic innovation leader, and iHuman Institute at ShanghaiTech University announced today a new research collaboration applying RuiYi's iCAPS (Intermembranous Conformation Antigen Presenting System) technology to create novel monoclonal antibodies with specific binding to G protein coupled receptors (GPCRs) to...

2014-05-29 04:22:16

LONDON and BOSTON, May 29, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief Executive Officer and co-founder, will give a company presentation at the Jefferies 2014 Global Healthcare in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 2 June. In addition, Heptares will give presentations at the following industry and scientific...

2014-05-15 04:22:26

LONDON and BOSTON, May 15, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Fiona Marshall, Heptares' Chief Scientific Officer and co-founder, will give a company presentation at the UBS Global Healthcare Conference [https://www.ubs.com/global/en/investment-bank/key-investor-conferences/americas.html ] in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 19 May....

2014-03-27 08:34:12

Cannabinoid Receptor 1 is most recent GPCR to be targeted by RuiYi's iCAPS platform LA JOLLA, Calif. and SHANGHAI, March 27, 2014 /PRNewswire/ -- RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA. RuiYi has a pipeline of...

2014-03-26 04:21:13

LONDON and BOSTON, March 26, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by its Chief Executive Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry [https://www.biocentury.com/conferences/futureleaders/dates ] on 28 March 2014 will be webcast live. The presentation will take place at 9.30am ET in room 302/303 at the Millennium Broadway...

Heart Attack Patients May Soon Have Side Effect-Free Drug Option
2014-03-12 06:36:52

April Flowers for redOrbit.com - Your Universe Online A new drug designed to stop a heart attack in its tracks, while reducing the damage caused, all without side effects, is one step closer to development thanks to a group of Melbourne scientists from Monash University. New hope for thousands of people who experience heart attacks and heart failure is provided by the study, published in a recent issue of Proceedings of the National Academy of Sciences. A team of scientists, led by...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related